摘要
目的 探讨糖尿病合并肺结核临床治疗效果。方法 1 995～ 2 0 0 0年 6 6例随机分两组 ,设对照组 33例 ,常规化疗 (2 HRZS(E) / 1 2 HR) ,适当控制饮食 ,应用降糖药物 (胰岛素、二甲双胍 )。治疗组 33例在上述治疗基础上加用免疫调节剂 (胸腺素或转移因子 )治疗 3个月以上。结果 治疗组 3月末、6月末、1 4月末痰菌阴转率明显高于对照组 (P<0 .0 5 ) ,而治疗组 3个月也高于对照组 6个月。疗程结束时 ,病灶吸收及空洞闭合 ,治疗组明显高于对照组 (P<0 .0 5 ) ,统计学处理都有显著性差异。结论 糖尿病合并肺结核的治疗 ,抗痨规律全程用药 ,控制血糖 ,加用免疫调节剂 ,使痰阴转率高 ,病灶吸收和空洞闭合快 ,缩短疗程 ,减少副作用 ,降低传染源 。
Objective To study the treatment effects of pulmonary TB patients concomitant with diabetes mellitus. Methods 66 patients from 1995 to 2000 in the hospital records were randomized into two groups in comparison with a control group of 33 cases. Besides changing food styles and using glucose-decreasing drugs (2HRZS(E)/12HR), the treatment group was also administrated with immune-regulatory agents such as thymosin or transfer factor at least for three months. Results Compared with the control patients, the treatment group was better as indicated sputumsmear-negative rate (p<0.05), in lesion-absorbing and cavity-closure (p<0.05), at the end of third month, sixth month, and fourteenth month (p<0.05).Conclusion In treating patients with pulmonary TB accompanied by DM, the use of immune regulatory agents was effective in lesion absorption, sputum smear negative, and cavity closure.
出处
《临床肺科杂志》
2004年第4期357-358,共2页
Journal of Clinical Pulmonary Medicine
关键词
肺结核
糖尿病
免疫调节剂
Pulmonary tuberculosis Diabetes mellitus Immune regulatory agent
